R. Addeo, S. Zappavigna, and C. Parlato, Erlotinib: early clinical development in brain cancer, Expert Opinion on Investigational Drugs, vol.63, issue.4, pp.1027-1037, 2014.
DOI : 10.1093/jnci/dji161

M. Al-hajj, M. S. Wicha, and A. Benito-hernandez, Prospective identification of tumorigenic breast cancer cells, Proceedings of the National Academy of Sciences, vol.17, issue.9, pp.3983-3988, 2003.
DOI : 10.1038/nm0901-1028

D. R. Alessi, M. Andjelkovic, and B. Caudwell, Mechanism of activation of protein kinase B by insulin and IGF-1, EMBO J, vol.15, issue.23, pp.6541-6551, 1996.

S. Bao, Q. Wu, and R. E. Mclendon, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.8, issue.7120, pp.756-760, 2006.
DOI : 10.1038/nn1473

C. A. Barker, A. J. Bishop, and M. Chang, Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival, International Journal of Radiation Oncology*Biology*Physics, vol.86, issue.3, pp.504-509, 2013.
DOI : 10.1016/j.ijrobp.2013.02.012

URL : http://europepmc.org/articles/pmc4667941?pdf=render

S. Berendsen, M. Broekman, and T. Seute, Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results, Expert Opinion on Investigational Drugs, vol.52, issue.2, pp.1391-1415, 2012.
DOI : 10.1055/s-2008-1046473

P. Bezecny, Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience, Medical Oncology, vol.31, issue.suppl 4, p.985, 2014.
DOI : 10.1200/JCO.2013.49.6968

C. Calabrese, H. Poppleton, and M. Kocak, A Perivascular Niche for Brain Tumor Stem Cells, Cancer Cell, vol.11, issue.1, pp.69-82, 2007.
DOI : 10.1016/j.ccr.2006.11.020

A. Capela and S. Temple, LeX/ssea-1 Is Expressed by Adult Mouse CNS Stem Cells, Identifying Them as Nonependymal, Neuron, vol.35, issue.5, pp.865-875, 2002.
DOI : 10.1016/S0896-6273(02)00835-8

URL : https://doi.org/10.1016/s0896-6273(02)00835-8

C. Cottin and S. , Expression et localisation de la connexine 43 dans le glioblastome: implication pour la thérapie génique, 2008.

A. K. Chan, J. C. Pang, and N. Y. Chung, Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors, Modern Pathology, vol.15, issue.3, pp.332-342, 2014.
DOI : 10.1158/1078-0432.CCR-09-0867

J. Chen, Y. Li, and T. S. Yu, A restricted cell population propagates glioblastoma growth after chemotherapy, Nature, vol.2, issue.7412, pp.522-526, 2012.
DOI : 10.1038/nature11287

URL : http://europepmc.org/articles/pmc3427400?pdf=render

E. A. Chiocca, Oncolytic viruses, Nature Reviews Cancer, vol.2, issue.12, pp.938-950, 2002.
DOI : 10.1038/nrc948

URL : https://hal.archives-ouvertes.fr/inserm-01644345

F. Ciardiello and G. Tortora, EGFR Antagonists in Cancer Treatment, New England Journal of Medicine, vol.358, issue.11, pp.1160-1174, 2008.
DOI : 10.1056/NEJMra0707704

M. F. Clarke, J. E. Dick, and P. B. Dirks, Cancer Stem Cells???Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells, Cancer Research, vol.66, issue.19, pp.9339-9344, 2006.
DOI : 10.1158/0008-5472.CAN-06-3126

URL : http://cancerres.aacrjournals.org/content/66/19/9339.full.pdf

A. T. Collins, P. A. Berry, and C. Hyde, Prospective Identification of Tumorigenic Prostate Cancer Stem Cells, Cancer Research, vol.65, issue.23, pp.10946-10951, 2005.
DOI : 10.1158/0008-5472.CAN-05-2018

F. Danhier, E. Ansorena, and J. M. Silva, PLGA-based nanoparticles: An overview of biomedical applications, Journal of Controlled Release, vol.161, issue.2, pp.505-522, 2012.
DOI : 10.1016/j.jconrel.2012.01.043

F. Danhier, K. Messaoudi, and L. Lemaire, Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation, International Journal of Pharmaceutics, vol.481, issue.1-2, pp.154-161, 2015.
DOI : 10.1016/j.ijpharm.2015.01.051

URL : https://hal.archives-ouvertes.fr/hal-01392431

D. Sousa, E. M. , I. Guessous, and L. Vermeulen, [Cancer stem cells and future therapeutic implications], Rev Med Suisse, vol.7, issue.289, pp.774-777, 2011.

G. Driessens, A. Beck, and . Caauwe, Defining the mode of tumour growth by clonal analysis, Nature, vol.96, issue.7412, pp.527-530, 2012.
DOI : 10.1038/nature11344

A. Eramo, F. Lotti, and G. Sette, Identification and expansion of the tumorigenic lung cancer stem cell population, Cell Death & Differentiation, vol.161, issue.3, pp.504-514, 2008.
DOI : 10.1126/science.273.5272.242

P. S. Eriksson, E. Perfilieva, and T. Bjork-eriksson, Neurogenesis in the adult human hippocampus, Nature Medicine, vol.383, issue.11, pp.1313-1317, 1998.
DOI : 10.1038/383624a0

. Eurostemcell, Cancer: une maladie des cellules souches ?, 2010.

X. Fan, L. Khaki, and T. S. Zhu, Notch Pathway Blockade Depletes CD133-Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts, Stem Cells, vol.28, issue.1, pp.5-16, 2010.
DOI : 10.1002/stem.254

D. Fang, T. K. Nguyen, and K. Leishear, A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas, Cancer Research, vol.65, issue.20, pp.9328-9337, 2005.
DOI : 10.1158/0008-5472.CAN-05-1343

. Fédération-pour-la-recherche-sur-le-cerveau, Les Tumeurs Cérébrales Retrieved 28, 2015.

S. Ferrandon, C. Malleval, and B. Hamdani, Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma, Molecular Cancer, vol.42, issue.1, p.134, 2015.
DOI : 10.1158/0008-5472.CAN-06-2306

URL : https://hal.archives-ouvertes.fr/hal-01214043

D. Figarella-branger, C. Colin, and A. Tchoghandjian, Glioblastomes??: oncogen??se et bases biologiques, Neurochirurgie, vol.56, issue.6, pp.441-448, 2010.
DOI : 10.1016/j.neuchi.2010.07.010

N. Y. Frank, A. Margaryan, and Y. Huang, ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma, Cancer Research, vol.65, issue.10, pp.4320-4333, 2005.
DOI : 10.1158/0008-5472.CAN-04-3327

W. R. Friedenberg, M. Rue, and E. A. Blood, Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95), Cancer, vol.104, issue.1, pp.830-838, 2006.
DOI : 10.1002/cncr.21666

H. S. Friedman, T. Kerby, and H. Calvert, Temozolomide and treatment of malignant glioma, Clin Cancer Res, vol.6, issue.7, pp.2585-2597, 2000.

H. S. Friedman, M. D. Prados, and P. Y. Wen, Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.27, issue.28, pp.4733-4740, 2009.
DOI : 10.1200/JCO.2008.19.8721

E. Galanis, K. A. Jaeckle, and M. J. Maurer, Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, Journal of Clinical Oncology, vol.27, issue.12, pp.2052-2058, 2009.
DOI : 10.1200/JCO.2008.19.0694

G. Seki, S. H. , M. Suzuki, O. Yamazaki, and H. Yamada, Pathophysiological Roles of Mutations in the Electrogenic Na+-HCO3-Cotransporter NBCe1. Mutations in Human Genetic Disease, pp.167-180, 2012.

J. Guyotat, Surgical management for glioblastoma: technological evolutions, Académie nationale de chirurgie, vol.12, pp.67-072, 2013.

S. Haberer, A. Assouline, and J. J. Mazeron, Gliomes c??r??braux, Cancer/Radioth??rapie, vol.14, issue.1, pp.14-22, 2010.
DOI : 10.1016/S1278-3218(10)70004-4

B. Hasselbalch, U. Lassen, and S. Hansen, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial, Neuro Oncol, vol.12, issue.5, pp.508-516, 2010.

J. He, Y. Liu, and T. Zhu, CD90 is Identified as a Candidate Marker for Cancer Stem Cells in Primary High-Grade Gliomas Using Tissue Microarrays, Molecular & Cellular Proteomics, vol.28, issue.6, pp.111-010744, 2012.
DOI : 10.1038/nature09557

J. M. Heddleston, Z. Li, and R. E. Mclendon, The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype, Cell Cycle, vol.8, issue.20, pp.3274-3284, 2009.
DOI : 10.4161/cc.8.20.9701

B. Herbert, A. E. Pitts, and S. I. Baker, Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death, Proceedings of the National Academy of Sciences, vol.18, issue.46, pp.96-14276, 1999.
DOI : 10.1038/sj.onc.1203069

J. H. Hong, D. Yang, and N. Shcheynikov, Convergence of IRBIT, phosphatidylinositol (4,5) bisphosphate, and WNK/SPAK kinases in regulation of the Na+-HCO3- cotransporters family, Proceedings of the National Academy of Sciences, vol.32, issue.suppl_2, pp.4105-4110, 2013.
DOI : 10.1093/nar/gkh468

A. F. Hottinger, R. Stupp, and K. Homicsko, Standards of care and novel approaches in the management of glioblastoma multiforme, Chinese Journal of Cancer, vol.33, issue.1, pp.32-39, 2014.
DOI : 10.5732/cjc.013.10207

J. T. Huse and E. C. Holland, Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma, Nature Reviews Cancer, vol.6, issue.5, pp.319-331, 2010.
DOI : 10.4161/cc.8.18.9504

T. N. Ignatova, V. G. Kukekov, and E. D. Laywell, Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro, Glia, vol.62, issue.3, pp.193-206, 2002.
DOI : 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C

E. Jacinto, V. Facchinetti, and D. Liu, SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity, Cell, vol.127, issue.1, pp.125-137, 2006.
DOI : 10.1016/j.cell.2006.08.033

URL : https://doi.org/10.1016/j.cell.2006.08.033

F. Keime-guibert, O. Chinot, and L. Taillandier, Radiotherapy for Glioblastoma in the Elderly, New England Journal of Medicine, vol.356, issue.15, pp.1527-1535, 2007.
DOI : 10.1056/NEJMoa065901

A. V. Krauze, S. D. Myrehaug, and M. G. Chang, A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma, International Journal of Radiation Oncology*Biology*Physics, vol.92, issue.5, pp.986-992, 2015.
DOI : 10.1016/j.ijrobp.2015.04.038

S. Kunjachan, B. Rychlik, and G. Storm, Multidrug resistance: Physiological principles and nanomedical solutions, Advanced Drug Delivery Reviews, vol.65, issue.13-14, pp.13-14, 2013.
DOI : 10.1016/j.addr.2013.09.018

URL : http://europepmc.org/articles/pmc3939439?pdf=render

Y. C. Kuo and Y. C. Chen, Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles, International Journal of Pharmaceutics, vol.479, issue.1, pp.138-149, 2015.
DOI : 10.1016/j.ijpharm.2014.12.070

M. Labussiere, M. Sanson, and A. Idbaih, IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?, The Oncologist, vol.15, issue.2, pp.196-199, 2010.
DOI : 10.1634/theoncologist.2009-0218

T. Lapidot, C. Sirard, and J. Vormoor, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature, vol.367, issue.6464, pp.645-648, 1994.
DOI : 10.1038/367645a0

C. Larsen, [14th scientific meeting of the Growth Factors Club Stem cells and cancer], Bull Cancer, vol.94, issue.3, pp.307-312, 2007.

C. Larsen, [Genetic and molecular abnormalities of glioblastomas (GBM)], Bull Cancer, vol.97, issue.11, pp.1389-1407, 2010.

U. Lassen, M. Sorensen, and T. B. Gaziel, Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme, Anticancer Res, vol.33, issue.4, pp.1657-1660, 2013.

E. Q. Lee, D. A. Reardon, and D. Schiff, Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma, Neuro-Oncology, vol.15, issue.3, 2015.
DOI : 10.1016/S1470-2045(14)70314-6

C. Li, D. G. Heidt, and P. Dalerba, Identification of Pancreatic Cancer Stem Cells, Cancer Research, vol.67, issue.3, pp.1030-1037, 2007.
DOI : 10.1158/0008-5472.CAN-06-2030

X. Li, Y. Liu, and K. J. Granberg, Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma, Oncogene, vol.67, issue.13, pp.1619-1628, 2015.
DOI : 10.1158/0008-5472.CAN-07-5019

. Ligue-contre-le-cancer, cellules souches cancéreuses: les racines du mal ?, 2015.

D. N. Louis, H. Ohgaki, and O. D. Wiestler, The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica, vol.64, issue.2, pp.97-109, 2007.
DOI : 10.1093/jnen/60.9.863

D. J. Ma, E. Galanis, and S. K. Anderson, A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K, Neuro-Oncology, vol.14, issue.(12), pp.1261-1269, 2015.
DOI : 10.1200/jco.2013.31.18_suppl.lba509

J. A. Mccormick and D. H. Ellison, The WNKs: Atypical Protein Kinases With Pleiotropic Actions, Physiological Reviews, vol.15, issue.1, pp.177-219, 2011.
DOI : 10.1042/BST0320817

S. Moniz and P. Jordan, Emerging roles for WNK kinases in cancer, Cellular and Molecular Life Sciences, vol.102, issue.8, pp.1265-1276, 2010.
DOI : 10.1152/physiol.00015.2006

B. Neyns, J. Sadones, and E. Joosens, Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma, Annals of Oncology, vol.117, issue.1, pp.1596-1603, 2009.
DOI : 10.1002/ijc.21121

F. Nottebohm, A brain for all seasons: cyclical anatomical changes in song control nuclei of the canary brain, Science, vol.214, issue.4527, pp.1368-1370, 1981.
DOI : 10.1126/science.7313697

. Oncolie, Neuro-oncologie de l'adulte : Glioblastome de l'adulte Retrieved 28, 2011.

Q. T. Ostrom, H. Gittleman, and P. Liao, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011, Neuro-Oncology, vol.94, issue.20, pp.1-63, 2014.
DOI : 10.1093/jnci/94.20.1537

C. Patru, L. Romao, and P. Varlet, CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors, BMC Cancer, vol.4, issue.5, p.66, 2010.
DOI : 10.1016/j.stem.2009.03.003

URL : https://hal.archives-ouvertes.fr/inserm-00663773

N. Pecuchet, T. Cluzeau, and C. Thibault, [Histone deacetylase inhibitors: highlight on epigenetic regulation], Bull Cancer, vol.97, issue.8, pp.917-935, 2010.

S. G. Piccirillo, B. A. Reynolds, and N. Zanetti, Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells, Nature, vol.156, issue.7120, pp.761-765, 2006.
DOI : 10.1006/exnr.1998.6998

P. Pourquier and J. Robert, [General overview on DNA repair], Bull Cancer, vol.98, issue.3, pp.229-237, 2011.

J. J. Raizer, L. E. Abrey, and A. B. Lassman, A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy, Neuro-Oncology, vol.318, issue.5848, pp.95-103, 2010.
DOI : 10.1126/science.1142946

M. Z. Ratajczak, M. Tarnowski, and S. Borkowska, The Embryonic Rest Hypothesis of Cancer Development: 150 Years Later, Trends in Stem Cell Proliferation and Cancer Research. H. U. E. Rodrigo R. Resende, pp.51-64, 2013.
DOI : 10.1007/978-94-007-6211-4_3

E. Razis, P. Selviaridis, and S. Labropoulos, Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment, Clinical Cancer Research, vol.15, issue.19, pp.6258-6266, 2009.
DOI : 10.1158/1078-0432.CCR-08-1867

D. A. Reardon, A. Desjardins, and J. J. Vredenburgh, Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, Journal of Neuro-Oncology, vol.65, issue.2, pp.219-230, 2010.
DOI : 10.1016/j.ijrobp.2006.01.018

D. A. Reardon, A. Desjardins, and J. J. Vredenburgh, Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma, Cancer, vol.97, issue.19, pp.4759-4767, 2012.
DOI : 10.1007/s11060-009-0008-0

D. A. Reardon, G. Freeman, and C. Wu, Immunotherapy advances for glioblastoma, Neuro-Oncology, vol.20, issue.18, pp.1441-1458, 2014.
DOI : 10.1097/WNR.0b013e32833188f7

URL : https://academic.oup.com/neuro-oncology/article-pdf/16/11/1441/7639930/nou212.pdf

J. Recamier, Recherches sur le traitement du cancer, par la compression méthodique simple ou combinée, et sur l'histoire général de la même maladie, 1829.

R. Remak, Ein Beitrag zur Entwicklungsgeschichte der Krebshaften geschwülste, D. Klinik, vol.6, pp.170-175, 1854.

T. Reya, S. J. Morrison, and M. F. Clarke, Stem cells, cancer, and cancer stem cells, Nature, vol.414, issue.6859, pp.105-111, 2001.
DOI : 10.1038/35102167

B. A. Reynolds and S. Weiss, Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system, Science, vol.255, issue.5052, pp.1707-1710, 1992.
DOI : 10.1126/science.1553558

L. Ricci-vitiani, D. G. Lombardi, and E. Pilozzi, Identification and expansion of human colon-cancer-initiating cells, Nature, vol.37, issue.7123, pp.111-115, 2007.
DOI : 10.1038/ng1005-1027

L. Ricci-vitiani, R. Pallini, and M. Biffoni, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, Nature, vol.200, issue.7325, pp.824-828, 2010.
DOI : 10.4161/cc.8.1.7533

J. N. Rich, D. A. Reardon, and T. Peery, Phase II Trial of Gefitinib in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.22, issue.1, pp.133-142, 2004.
DOI : 10.1200/JCO.2004.08.110

C. Richardson and D. R. Alessi, The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway, Journal of Cell Science, vol.121, issue.20, pp.3293-3304, 2008.
DOI : 10.1242/jcs.029223

W. Roa, P. M. Brasher, and G. Bauman, Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial, Journal of Clinical Oncology, vol.22, issue.9, pp.1583-1588, 2004.
DOI : 10.1200/JCO.2004.06.082

F. Sahm, C. Koelsche, and J. Meyer, CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas, Acta Neuropathologica, vol.226, issue.6, pp.853-860, 2012.
DOI : 10.1002/path.2995

J. H. Sampson, A. B. Heimberger, and G. E. Archer, Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.28, issue.31, pp.4722-4729, 2010.
DOI : 10.1200/JCO.2010.28.6963

D. D. Sarbassov, D. A. Guertin, and S. M. Ali, Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex, Science, vol.307, issue.5712, pp.1098-1101, 2005.
DOI : 10.1126/science.1106148

M. Schlaak, P. Schmidt, and C. Bangard, Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells, Oncotarget, vol.3, issue.1, pp.22-30, 2012.
DOI : 10.18632/oncotarget.437

J. Schuster, R. K. Lai, and L. D. Recht, A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study, Neuro-Oncology, vol.352, issue.10, pp.854-861, 2015.
DOI : 10.1056/NEJMoa043330

M. Shackleton, E. Quintana, and E. R. Fearon, Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution, Cell, vol.138, issue.5, pp.822-829, 2009.
DOI : 10.1016/j.cell.2009.08.017

S. K. Singh, C. Hawkins, and I. D. Clarke, Identification of human brain tumour initiating cells, Nature, vol.64, issue.suppl. 1, pp.396-401, 2004.
DOI : 10.1158/0008-5472.CAN-04-1364

K. L. Spalding, O. Bergmann, and K. Alkass, Dynamics of Hippocampal Neurogenesis in Adult Humans, Cell, vol.153, issue.6, pp.1219-1227, 2013.
DOI : 10.1016/j.cell.2013.05.002

URL : https://hal.archives-ouvertes.fr/hal-00839513

W. Stummer, U. Pichlmeier, and T. Meinel, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, The Lancet Oncology, vol.7, issue.5, pp.392-401, 2006.
DOI : 10.1016/S1470-2045(06)70665-9

R. Stupp, M. E. Hegi, and W. P. Mason, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-466, 2009.
DOI : 10.1016/S1470-2045(09)70025-7

R. Stupp, W. P. Mason, M. J. Van-den, and . Bent, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-996, 2005.
DOI : 10.1056/NEJMoa043330

T. Sun, N. M. Warrington, and J. Luo, Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males, Journal of Clinical Investigation, vol.124, issue.9, pp.4123-4133, 2014.
DOI : 10.1172/JCI71048DS1

URL : http://www.jci.org/articles/view/71048/files/pdf

R. Sutter, G. Yadirgi, and S. Marino, Neural stem cells, tumour stem cells and brain tumours: Dangerous relationships?, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1776, issue.2, pp.125-137, 2007.
DOI : 10.1016/j.bbcan.2007.07.006

M. Suzuki, G. Seki, and H. Yamada, Functional Roles of Electrogenic Sodium Bicarbonate Cotransporter NBCe1 in Ocular Tissues, The Open Ophthalmology Journal, vol.6, issue.1, pp.36-41, 2012.
DOI : 10.2174/1874364101206010036

M. Suzuki, W. Van-paesschen, and I. Stalmans, Defective membrane expression of the Na+-HCO3- cotransporter NBCe1 is associated with familial migraine, Proceedings of the National Academy of Sciences, vol.103, issue.25, pp.15963-15968, 2010.
DOI : 10.1073/pnas.0602250103

K. Takahashi and S. Yamanaka, Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors, Cell, vol.126, issue.4, pp.663-676, 2006.
DOI : 10.1016/j.cell.2006.07.024

M. S. Tallman, C. Nabhan, and J. H. Feusner, Acute promyelocytic leukemia: evolving therapeutic strategies, Blood, vol.99, issue.3, pp.759-767, 2002.
DOI : 10.1182/blood.V99.3.759

URL : http://www.bloodjournal.org/content/bloodjournal/99/3/759.full.pdf

M. Tamura, J. Gu, and H. Tran, PTEN Gene and Integrin Signaling in Cancer, JNCI Journal of the National Cancer Institute, vol.96, issue.11, pp.1820-1828, 1999.
DOI : 10.1073/pnas.96.11.6199

S. M. Theparambil, I. Ruminot, and H. P. Schneider, The Electrogenic Sodium Bicarbonate Cotransporter NBCe1 Is a High-Affinity Bicarbonate Carrier in Cortical Astrocytes, Journal of Neuroscience, vol.34, issue.4, pp.1148-1157, 2014.
DOI : 10.1523/JNEUROSCI.2377-13.2014

M. Todaro, M. P. Alea, and A. B. Di-stefano, Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4, Cell Stem Cell, vol.1, issue.4, pp.389-402, 2007.
DOI : 10.1016/j.stem.2007.08.001

G. Tosi, B. Bortot, and B. Ruozi, Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier, Current Medicinal Chemistry, vol.20, issue.17, pp.2212-2225, 2013.
DOI : 10.2174/0929867311320170006

H. C. Tsai, K. C. Wei, and C. N. Tsai, Effect of valproic acid on the outcome of glioblastoma multiforme, British Journal of Neurosurgery, vol.16, issue.3, pp.347-354, 2012.
DOI : 10.3727/096504007783338340

M. J. Van-den-bent, M. E. Hegi, and R. Stupp, Recent developments in the use of chemotherapy in brain tumours, European Journal of Cancer, vol.42, issue.5, pp.582-588, 2006.
DOI : 10.1016/j.ejca.2005.06.031

E. G. Van-meir, C. G. Hadjipanayis, and A. D. Norden, Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma, CA: A Cancer Journal for Clinicians, vol.60, issue.3, pp.166-193, 2010.
DOI : 10.3322/caac.20069

A. L. Vescovi, R. Galli, and B. A. Reynolds, Brain tumour stem cells, Nature Reviews Cancer, vol.6, issue.6, pp.425-436, 2006.
DOI : 10.1593/neo.03427

J. J. Vredenburgh, A. Desjardins, and J. E. Herndon, Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaBevacizumab plus irinotecan in recurrent glioblastoma multiformeNotch promotes radioresistance of glioma stem cells, Clin Cancer Res J Clin Oncol Stem Cells, vol.13, issue.281, pp.1253-1259, 2007.

K. Watanabe, O. Tachibana, and K. Sata, Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas, Brain Pathology, vol.3, issue.3, pp.217-223, 1996.
DOI : 10.1002/ijc.2910560608

T. Watanabe, S. Nobusawa, and P. Kleihues, IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas, The American Journal of Pathology, vol.174, issue.4, pp.1149-1153, 2009.
DOI : 10.2353/ajpath.2009.080958

F. M. Watt and B. L. Hogan, Out of Eden: Stem Cells and Their Niches, Science, vol.287, issue.5457, pp.1427-1430, 2000.
DOI : 10.1126/science.287.5457.1427

P. Y. Wen, W. K. Yung, and K. R. Lamborn, Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08, Clinical Cancer Research, vol.12, issue.16, pp.4899-4907, 2006.
DOI : 10.1158/1078-0432.CCR-06-0773

S. R. Woo, Y. T. Oh, and J. Y. An, Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness, Anatomy & Cell Biology, vol.48, issue.1, pp.44-53, 2015.
DOI : 10.5115/acb.2015.48.1.44

URL : http://europepmc.org/articles/pmc4371180?pdf=render

D. Yang, Q. Li, and I. So, IRBIT governs epithelial secretion in mice by antagonizing the WNK/SPAK kinase pathway, Journal of Clinical Investigation, vol.121, issue.3, pp.956-965, 2011.
DOI : 10.1172/JCI43475DS1

Y. Yuan, W. Xiang, and M. Qing, Survival analysis for valproic acid use in adult glioblastoma multiforme: A meta-analysis of individual patient data and a systematic review, Seizure, vol.23, issue.10, pp.830-835, 2014.
DOI : 10.1016/j.seizure.2014.06.015

M. Zeniou, M. Feve, and S. Mameri, Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells, PLOS ONE, vol.138, issue.4, p.134793, 2015.
DOI : 10.1371/journal.pone.0134793.s015

URL : https://hal.archives-ouvertes.fr/hal-01223842

J. Zhu, J. Zuo, and Q. Xu, Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients, Medical Hypotheses, vol.76, issue.4, pp.602-603, 2011.
DOI : 10.1016/j.mehy.2011.01.011

Q. Zhu, L. Kao, and R. Azimov, Topological Location and Structural Importance of the NBCe1-A Residues Mutated in Proximal Renal Tubular Acidosis, Journal of Biological Chemistry, vol.281, issue.18, pp.13416-13426, 2010.
DOI : 10.1006/meth.1998.0615